MM-005: A Phase 1 Trial Of Pomalidomide, Bortezomib, and Low-Dose Dexamethasone (PVD) In Relapsed and/Or Refractory Multiple Myeloma (RRMM)

被引：1
|
作者：
Richardson, Paul G.
Hofmeister, Craig C.
Siegel, David
Lonial, Sagar
Laubach, Jacob P.
Efebera, Yvonne A.
Vesole, David H.
Nooka, Ajay K.
Rosenblatt, Jacalyn
Raje, Noopur
Zaki, Mohamed H.
Hua, Ye
Li, Yan
Shah, Sheetal
Wang, Jianming
Anderson, Kenneth C.
机构：
来源：
BLOOD | 2013年 / 122卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1969
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pomalidomide Plus Low-Dose Dexamethasone (POM plus LoDEX) for Relapsed and Refractory Multiple Myeloma (RRMM): Results from a Pharmacoeconomic Evaluation
    Schey, Steve
    Dhanasiri, Sujith
    Lee, Dawn
    Sternas, Lars
    Yu, Xin
    Zaki, Mohamed H.
    Elvidge, Jamie
    O'Dwyer, Michael
    BLOOD, 2014, 124 (21)
  • [32] Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma
    Weisel, Katja
    Dimopoulos, Meletios
    Moreau, Philippe
    Yagci, Munci
    Larocca, Alessandra
    Kanate, Abraham S.
    Vural, Filiz
    Cascavilla, Nicola
    Basu, Supratik
    Johnson, Peter
    Byeff, Peter
    Hus, Marek
    Rodriguez-Otero, Paula
    Muelduer, Ercan
    Anttila, Pekka
    Hayden, Patrick J.
    Krauth, Maria-Theresa
    Lucio, Paulo
    Ben-Yehuda, Dina
    Mendeleeva, Larisa
    Guo, Shien
    Yu, Xin
    Grote, Lara
    Biyukov, Tsvetan
    Dhanasiri, Sujith
    Richardson, Paul
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 1850 - 1859
  • [33] Long-term safety and efficacy of pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in relapsed and refractory multiple myeloma (RRMM) patients enrolled in the MM-002 phase II trial
    Siegel, David Samuel DiCapua
    Richardson, Paul Gerard Guy
    Vij, Ravi
    Hofmeister, Craig C.
    Baz, Rachid C.
    Jagannath, Sundar
    Chen, Christine
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Bahlis, Nizar J.
    Song, Kevin W.
    Belch, Andrew
    Raje, Noopur S.
    Shustik, Chaim
    Lentzsch, Suzanne
    Chen, Min
    Zaki, Mohamed H.
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [34] Pomalidomide (POM) with Low-Dose Dexamethasone (LoDEX) in Patients with Relapsed and Refractory Multiple Myeloma (RRMM): Outcomes Based on Prior Treatment Exposure
    Vij, Ravi
    Hofmeister, Craig C.
    Richardson, Paul G.
    Jagannath, Sundar
    Siegel, David S.
    Baz, Rachid
    Chen, Min
    Zaki, Mohamed
    Larkins, Gail
    Anderson, Kenneth C.
    BLOOD, 2012, 120 (21)
  • [35] POMALIDOMIDE-DEXAMETHASONE (PD) VS POMALIDOMIDE-BORTEZOMIB-DEXAMETHASONE (PVD) / POMALIDOMIDE-CYCLOPHOSPHAMIDE-DEXAMETHASONE (PCD) IN RELAPSE OR REFRACTORY MM (RRMM)
    Gil Perez, A.
    Guillen Garcia, H.
    Vazquez Ramo, A.
    Perez Ortega, A.
    Nuevo Lopez, I
    Juarez Salcedo, L. M.
    Dolores Subira, P.
    De Miguel Llorente, D.
    HAEMATOLOGICA, 2018, 103 : 119 - 120
  • [36] Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Schlossman, Robert L.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Reimonn, Cassandra A.
    Andrade, Danielle X.
    Redd, Robert
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD ADVANCES, 2025, 9 (05) : 1163 - 1170
  • [37] Pomalidomide plus low-dose dexamethasone (POM plus LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003
    Goldschmidt, Hartmut
    Dimopoulos, Meletios A.
    Weisel, Katja C.
    Moreau, Philippe
    Lacy, Martha
    Song, Kevin W.
    Delforge, Michel
    Karlin, Lionel
    Banos, Anne
    Rocafiguera, Albert Oriol
    Yu, Xin
    Sternas, Lars
    Jacques, Christian
    Zaki, Mohamed H.
    San-Miguel, Jesus F.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [38] Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).
    Richardson, Paul G.
    Perrot, Aurore
    San-Miguel, Jesus F.
    Beksac, Meral
    Spicka, Ivan
    Leleu, Xavier
    Schjesvold, Fredrik
    Moreau, Philippe
    Dimopoulos, Meletios A.
    Huang, Jeffrey Sy.
    Minarik, Jiri
    Cavo, Michele
    Prince, H. Miles
    Zheng, Cheng
    Dubin, Franck
    Van de Velde, Helgi
    Anderson, Kenneth Carl
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL IMPAIRMENT: PHASE 1 PHARMACOKINETICS AND SAFETY
    Matous, J.
    Siegel, D.
    Lonial, S.
    Harvey, R. D.
    Kasserra, C.
    Li, Y.
    Chen, M.
    Doerr, T.
    Sternas, L.
    Zaki, M.
    Jacques, C.
    Shah, J.
    HAEMATOLOGICA, 2015, 100 : 507 - 508
  • [40] Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial
    Dimopoulos, Meletios
    Weisel, Katja
    van de Donk, Niels W. C. J.
    Ramasamy, Karthik
    Gamberi, Barbara
    Streetly, Matthew
    Offidani, Massimo
    Bridoux, Frank
    de la Rubia, Javier
    Mateos, Maria-Victoria
    Ardizzoia, Antonio
    Kueenburg, Elisabeth
    Collins, Shona
    Di Micco, Antonia
    Rosettani, Barbara
    Li, Yan
    Bacon, Pamela
    Sonneveld, Pieter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (20) : 2035 - +
12345